Molecular markers of outcome after radiotherapy in patients with prostate carcinoma: Ki-67, bcl-2, bax, and bcl-x

Cancer

Volumn 97, Issue 7, 2003, Pages 1630-1638

  Pollack, Alan ^a   Cowen, Didier ^b   Troncoso, Patricia ^c   Zagars, Gunar K ^c   Von Eschenbach, Andrew C ^c   Meistrich, Marvin L ^c   McDonnell, Timothy ^c  

^a FOX CHASE CANCER CENTER   (United States)

^b TIMONE HOSPITAL   (France)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Bax; Bcl 2; Bcl x; MIB 1; Prostate carcinoma; Prostate specific antigen; Radiotherapy

Indexed keywords

KI 67 ANTIGEN; PROSTATE SPECIFIC ANTIGEN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL X;

ARTICLE; BEAM THERAPY; CANCER RADIOTHERAPY; CONTROLLED STUDY; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE BIOPSY; PROSTATE CARCINOMA; PROTEIN EXPRESSION; RADIATION DOSE; TRANSURETHRAL RESECTION; TREATMENT OUTCOME;

BCL-2-ASSOCIATED X PROTEIN; BCL-X PROTEIN; BIOPSY; CARCINOMA; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 0037378596     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11230     Document Type: Article

References (55)

1. Korsmeyer SJ. Bcl-2 initiates a new category of oncogenes: regulators of cell death. Blood. 1992;80:879-886.
2. Raffo AJ, Perlman H, Chen M-W, et al. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res. 1995;55:4438-4445.
3. Stattin P, Damber J-E, Karlberg L, Nordgren H, Bergh A. Bcl-2 immunoreactivity in prostate tumorigenesis in relation to prostatic intraepithelial neoplasia, grade, hormonal status, metastatic growth and survival. Urol Res. 1996;24: 257-264.
4. Lipponen P, Vesalainen S. Expression of the apoptosis suppressing protein bcl-2 in prostatic adenocarcinoma is related to tumor malignancy. Prostate. 1997;3:9-15.
5. McDonnell TJ, Troncoso P, Brisbay SM, et al. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res. 1992;52:6940-6944.
6. Colombel M, Symmans F, Gil S, et al. Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone-refractory human prostate cancers. Am J Pathol. 1993;143: 390-400.
7. Apakama I, Robinson MC, Walter NM, et al. Bcl-2 overexpression combined with p53 protein accumulation correlates with hormone-refractory prostate cancer. Br J Cancer. 1996;74:1258-1262.
8. Furuya Y, Krajewski S, Epstein JI, Reed JC, Isaacs JT. Expression of bcl-2 and the progression of human and rodent prostatic cancers. Clin Cancer Res. 1996;2:389-398.
9. Szende B, Romics I, Torda I, Bély M, Szegedi Zs, Lovász S. Apoptosis, mitosis, p53, bcl2, ki-67 and clinical outcome in prostate carcinoma treated by androgen ablation. Urol Int. 1999;63:115-119.
10. Kajiwara T, Takeuchi T, Ueki T, et al. Effect of bcl-2 overexpression in human prostate cancer cells in vitro and in vivo. Int J Urol. 1999;6:520-525.
11. Westin P, Lo P, Marin CM, et al. Bcl-2 expression confers androgen independence in androgen sensitive prostatic carcinoma. Int J Oncol. 1997;10:113-118.
12. Gleave ME, Miayake H, Goldie J, Nelson C, Tolcher A. Targeting bcl-2 gene to delay androgen-independent progression and enhance chemosensitivity in prostate cancer using antisense bcl-2 oligodeoxynucleotides. Urology. 1999;54:36-46.
13. Miyake H, Tolcher A, Gleave ME. Antisense bcl-2 oligodeoxynucleotides inhibit progression in androgen-independence after castration in the Shionogi tumor model. Cancer Res. 1999;59:4030-4034.
14. Bubendorf L, Sauter G, Moch H, et al. Prognostic significance of bcl-2 in clinically localized prostate cancer. Am J Pathol. 1996;148:1557-1565.
15. Moul JW, Bettencourt MC, Sesterhenn IA, et al. Protein expression of p53, bcl-2, and KI-67 (MIB-1) as prognostic biomarkers in patients with surgically treated, clinically localized prostate cancer. Surgery. 1996;120:159-166.
16. Matsushima H, Kitamura T, Goto T, Hosaka Y, Homma Y, Kawabe K. Combined analysis with bcl-2 and p53 immunostaining predicts poorer prognosis in prostatic carcinoma. J Urol. 1997;158:2278-2283.
17. Stackhouse GB, Sesterhenn IA, Bauer JJ, et al. P53 and bcl-2 immunohistochemistry in pretreatment prostate needle biopsies to predict recurrence of prostate cancer after radical prostatectomy. J Urol. 1999;162:2040-2045.
18. Brewster SF, Oxley JD, Trivella M, Abbott CD, Gillatt DA. Preoperative p53, bcl-2, CD44 and e-cadherin immunohistochemistry as predictors of biochemical relapse after radical prostatectomy. J Urol. 1999;162:1238-1243.
19. Theodorescu D, Broder SF, Boyd JC, Mills SE, Frierson HF Jr. P53, bcl-2 and retinoblastoma proteins as long-term prognostic markers in localized carcinoma of the prostate. J Urol. 1997;158:131-137.
20. Borre M, Stausbøl-Grøn B, Overgaard J. p53 accumulation associated with bcl-2, the proliferation marker MIB-1 and survival in patients with prostate cancer subjected to watchful waiting. J Urol. 2000;164:716-721.
21. Bylund A, Stattin P, Widmark A, Bergh A. Predictive value of bcl-2 immunoreactivity in prostate cancer patients treated with radiotherapy. Radiother Oncol. 1998;49:143-148.
22. Mackey TJ, Borkowski A, Amin P, Jacobs SC, Kyprianou N. Bcl-2/bax ratio as a predictive marker for therapeutic response to radiotherapy in patients with prostate cancer. Urology. 1998;52:1085-1090.
23. Scherr DS, Vaughan ED Jr., Wei J, et al. Bcl-2 and p53 expression in clinically localized prostate cancer predicts response to external beam radiotherapy. J Urol. 1999;162: 12-17.
24. Szostak MJ, Kaur P, Amin P, Jacobs SC, Kyprianou N. Apoptosis and bcl-2 expression in prostate cancer: significance in clinical outcome after brachytherapy. J Urol. 2001;165(6 Pt 1):2126-2130.
25. Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell. 1993;74:609-619.
26. Li X, Marani M, Yu J, et al. Adenovirus-mediated Bax overexpression for the induction of therapeutic apoptosis in prostate cancer. Cancer Res. 2001;61:186-191.
27. Boise LH, Gonzalez-Garcia M, Postema CE, et al. bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell. 1993;74:597-608.
28. Chao DT, Linette GP, Boise LH, White LS, Thompson CB, Korsmeyer SJ. Bcl-XL and Bcl-2 repress a common pathway of cell death. J Exp Med. 1995;182:821-828.
29. Sedlak TW, Oltvai ZN, Yang E, et al. Multiple Bcl-2 family members demonstrate selective dimerizations with Bax. Proc Natl Acad Sci USA. 1995;92:7834-7838.
30. Clarke MF, Apel IJ, Benedict MA, et al. A recombinant bcl-Xs adenovirus selectively induces apoptosis in cancer cells but not in normal bone marrow cells. Proc Natl Acad Sci USA. 1995;92:11024-11028.
31. Krajewska M, Krajewski S, Epstein JI, et al. Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. Am J Pathol. 1996;148:1567-1576.
32. Johnson MI, Robinson MC, Marsh C, Robson CN, Neal DE, Hamdy FC. Expression of bcl-2, bax, and p53 in high grade prostatic intraepithelial neoplasia and localized prostate cancer: relationship with apoptosis and proliferation. Prostate. 1998;37:223-229.
33. Chia SJ, Tang WY, Elnatan J, Yap WM, Goh HS, Smith DR. Prostate tumors from an Asian population: examination of bxa, bcl-2, p53 and ras and identification of bax as a prognostic marker. Br J Cancer. 2000;83:761-768.
34. Li B, Dou QP. Bax degradation by the ubiquitin/proteasome-dependent pathway: involvement in tumor survival and progression. Proc Natl Acad Sci USA. 2000;97:3850-3855.
35. Royela M, De Miguel MP, Bethencourt FR, Fraile B, Arenas MI, Paniagua R. IL-2, its receptors, and bcl-2 and bax genes in normal, hyperplastic and carcinomatous human prostates: immunohistochemical comparative analysis. Growth Factors. 2000;18:135-146.
36. Cowen D, Troncoso P, Khoo VS, et al. Ki-67 staining is an independent correlate of biochemical failure in prostate cancer treated with radiotherapy. Clin Cancer Res. 2002;8: 1148-1154.
37. Pollack A, Zagars GK, Smith LG, et al. Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. J Clin Oncol. 2000;18:3904-3911.
38. Beahrs OH, Henson DE, Hutter RVP, Kennedy BJ, editors. AJCC manual for staging of cancer, 4th edition. Philadelphia: JB Lippincott Company, 1992:181-183.
39. Khoo VS, Pollack A, Cowen D, et al. Relationship of Ki-67 labeling index to DNA-ploidy, S-phase fraction, and outcome in prostate cancer treated with radiotherapy. Prostate. 1999;41:166-172.
40. Pollack A, Wu CS, Czerniak B, et al, Abnormal bcl-2 and pRb expression are independent correlates of radiation response in muscle-invasive bladder cancer. Clin Cancer Res. 1997;3: 1823-1829.
41. American Society for Therapeutic Radiology and Oncology Consensus Panel. Consensus statement: guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys. 1997;37:1035-1041.
42. Harris EK, Albert A. Survivorship analysis for clinical studies. New York: Marcel Dekker, Inc., 1991:5-125.
43. Cox DR, Oakes D. Analysis of survival data. London: Chapman and Hall, 1984:110-120.
44. Dorai T, Perlman H, Walsh K, et al. A recombinant defective adenoviral agent expressing anti-bcl-2 ribozyme promotes apoptosis of bcl-2-expressing human prostate cancer cells. Int J Cancer. 1999;82:846-852.
45. Hendry JH, Potten CS. Intestinal cell radiosensitivity: a comparison for cell death assayed by apoptosis or by a loss of clonogenicity. Int J Radiat Biol Relat Stud Phys Chem Med. 1982;42:621-628.
46. Lim Joon D, Hasegawa M, Sikes C, et al. Supraadditive apoptotic response of R3327-G rat prostate tumors to androgen ablation and radiation. Int J Radiat Oncol Biol Phys. 1997;38:1071-1077.
47. Kyprianou N, King ED, Bradbury D, Rhee JG. Bcl-2 overexpression delays radiation-induced apoptosis without affecting the clonogenic survival of human prostate cancer cells. Int J Cancer. 1997;70:341-348.
48. Pollack A, Ashoori F, Sikess C, et al. The early supra-additive apoptotic response of R3327-G prostate tumors to androgen ablation and radiation is not sustained with multiple fractions. Int J Radiat Oncol Biol Phys. 1999;46:153-158.
49. Pollack A, Salem N, Ashoori F, et al. Lack of prostate cancer radiosensitization by androgen deprivation. Int J Radiat Oncol Biol Phys. 2001;51:1002-1007.
50. Sentman CL, Shutter JR, Hockenbery D, Kanagawa O, Korsmeyer SJ. bcl-2 inhibits multiple forms of apoptosis but not negative selection in thymocytes. Cell. 1991;67:879-888.
51. Huang A, Gandour-Edwards R, Rosenthal SA, Siders DB, Deitch AD, White RW. P53 and bcl-2 immunohistochemical alterations in prostate cancer treated with radiation therapy. Urology. 1998;51:346-351.
52. Rakozy C, Grignon DJ, Sarkar FH, Sakr WA, Littrup P, Forman J. Expression of bcl-2, p53, and p21 in benign and malignant prostatic tissue before and after radiation therapy. Mod Pathol. 1998;11:892-899.
53. Grossfeld GD, Olumi AF, Connolly JA, et al. Locally recurrent prostate tumors following either radiation therapy or radical prostatectomy have changes in Ki-67 labeling index, p53 and bcl-2 immunoreactivity. J Urol. 1998;159:1437-1443.
54. Bruckheimer EM, Cho S, Brisbay S, et al. The impact of bcl-2 expression and bax deficiency on prostate homeostasis in vivo. Oncogene. 2000;19:2404-2412.
55. Buckheimer EM, Brisbay S, Johnson DJ, Gingrich JR, Greenberg N, McDonnell TJ. Bcl-2 accelerates multistep prostate carcinogenesis in vivo. Oncogene. 2000;19:5251-5258.